Reports published annually by the appropriations committees do not rank high in the hierarchy of legislative documents.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
